Eloxx Pharmaceuticals Inc (ELOX)

NASDAQHealth CareBiotechnologySnapshot 2026-10-26

$13.17+2.89%

Close 2026-10-26 · 1-day change

Investment OutlookAs of Oct 26, 2026

What could strengthen or challenge Eloxx Pharmaceuticals Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Oct 10, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	1.75M
EPS	—	-0.657
Annual ending 2026-12-31
Revenue	—	0
EPS	—	-2.228
Annual ending 2027-12-31
Revenue	—	173.81M
EPS	—	-2.533

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Manage capital allocation and equity financing activities	A supporting condition in Eloxx Pharmaceuticals Inc's published investment case. The stated target is Secure additional funding to support operations through 2026.	Intact	Failure to secure necessary funding by mid-2026	Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 26, 2026Last status assessment Oct 26, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated in 2 quarters: 2025-Q2 and 2026-Q2 via material events filings. The company issued prefunded warrants and modified rights of security holders to raise capital. No direct financial impact figures are provided, but these actions indicate ongoing capital allocation efforts to support operations. The trajectory is consistent with maintaining liquidity through equity financing. Delivery assessment Oct 26, 2026
Advance clinical development and business updates	A primary condition in Eloxx Pharmaceuticals Inc's published investment case. The stated target is Continue advancing clinical programs through 2026.	Intact	Failure to progress in clinical trials by the end of 2026	Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 26, 2026Last status assessment Oct 26, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Newly stated in 2026-Q2 with a press release providing financial results and a business update. Financials show operating losses of $4.45M and net losses of $4.5M in 2026-Q2, consistent with ongoing development-stage operations. The trajectory reflects continued investment in clinical and business activities without revenue generation yet. Delivery assessment Oct 26, 2026
Manage operating expenses and cash flow	A supporting condition in Eloxx Pharmaceuticals Inc's published investment case. The stated target is Maintain operating losses below $4.5M per quarter.	Under Pressure	Operating losses exceed $4.5M in any quarter	Operating income: $-4.45M FY2026-Q2; GAAP. Published target: Maintain operating losses below $4.5M per quarter. Target period is not explicitly aligned with this observation. Source published Aug 11, 2026-4,450,000 USD · source valueSource reportLast status assessment Oct 26, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 4ea47d58-199f-4659-9720-0700cda62105. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated or implied in 6 quarters from 2023-Q3 through 2026-Q2. Operating income losses ranged from -$1.22M in 2025-Q1 to -$4.45M in 2026-Q2, with net losses similarly increasing to -$4.5M in 2026-Q2. The trajectory shows increasing operating losses consistent with ongoing development expenses, indicating limited progress in reducing operating losses. Delivery assessment Oct 26, 2026

Stored thesis · Oct 10, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-09-07	Unavailable	Unavailable	2 / 1
2026-09-08	Unavailable	Unavailable	2 / 1
2026-09-09	Unavailable	Unavailable	2 / 1
2026-09-10	Unavailable	Unavailable	2 / 1
2026-09-11	Unavailable	Unavailable	2 / 1
2026-09-12	Unavailable	Unavailable	2 / 1
2026-09-13	Unavailable	Unavailable	2 / 1
2026-09-14	Unavailable	Unavailable	2 / 1
2026-09-15	Unavailable	Unavailable	2 / 1
2026-09-16	Unavailable	Unavailable	2 / 1
2026-09-17	Unavailable	Unavailable	2 / 1
2026-09-18	Unavailable	Unavailable	2 / 1
2026-09-19	Unavailable	Unavailable	2 / 1
2026-09-20	Unavailable	Unavailable	2 / 1
2026-09-21	Unavailable	Unavailable	3 / 1
2026-09-22	Unavailable	Unavailable	3 / 1
2026-09-23	Unavailable	Unavailable	3 / 1
2026-09-24	Unavailable	Unavailable	3 / 1
2026-09-25	Unavailable	Unavailable	3 / 1
2026-09-26	Unavailable	Unavailable	3 / 1
2026-09-27	Unavailable	Unavailable	3 / 1
2026-09-28	Unavailable	Unavailable	3 / 1
2026-09-29	Unavailable	Unavailable	3 / 1
2026-09-30	Unavailable	Unavailable	3 / 1
2026-10-01	Unavailable	Unavailable	3 / 1
2026-10-02	Unavailable	Unavailable	3 / 1
2026-10-03	Unavailable	Unavailable	3 / 1
2026-10-04	Unavailable	Unavailable	3 / 1
2026-10-05	Unavailable	Unavailable	3 / 1
2026-10-06	Unavailable	Unavailable	3 / 1
2026-10-07	Unavailable	Unavailable	3 / 1
2026-10-08	Unavailable	Unavailable	3 / 1
2026-10-09	Unavailable	Unavailable	3 / 1
2026-10-10	Unavailable	Unavailable	3 / 1
2026-10-11	Unavailable	Unavailable	3 / 1
2026-10-12	Unavailable	Unavailable	3 / 1
2026-10-13	Unavailable	Unavailable	3 / 1
2026-10-14	Unavailable	Unavailable	3 / 1
2026-10-15	Unavailable	Unavailable	3 / 1
2026-10-16	Unavailable	Unavailable	3 / 1
2026-10-17	Unavailable	Unavailable	3 / 1
2026-10-18	Unavailable	Unavailable	2 / 1
2026-10-19	Unavailable	Unavailable	2 / 1
2026-10-20	Unavailable	Unavailable	2 / 1
2026-10-21	Unavailable	Unavailable	2 / 1
2026-10-22	Unavailable	Unavailable	2 / 1
2026-10-23	Unavailable	Unavailable	2 / 1
2026-10-24	Unavailable	Unavailable	2 / 1
2026-10-25	Unavailable	Unavailable	2 / 1
2026-10-26	Unavailable	Unavailable	2 / 1

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-07-01	2	0	0
2026-08-01	3	0	0
2026-09-01	4	0	0
2026-10-01	5	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 5 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 27–Oct 26 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 27, 2026–Oct 26, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Manage capital allocation and equity financing activitiesQualitative condition
Advance clinical development and business updatesQualitative condition
Manage operating expenses and cash flowPublished status: Under Pressure

Next proof point

Nov 10, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

3.4%Typical daily move · historical

Downside history

-41.8%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Eloxx Pharmaceuticals Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative, development-stage business rather than an established earnings compounder. The long-term thesis is in a watch state, with low overall confidence, weak recent performance, and high risk.

What's priced into Eloxx Pharmaceuticals Inc

The evidence does not provide a valuation measure or a clear account of market expectations, so whether ELOX is cheap or expensive versus peers cannot be assessed. No fragility gates fired, but that does not resolve the uncertainty around its losses and financing needs.

What the fundamentals likely do

Near term, the company is likely to remain loss-making as it continues clinical and business development without revenue generation yet. Second-quarter 2026 operating and net losses increased, while efforts to manage expenses are behind; equity financing has also supported operations. A recent president transition is noted, but its effect is unclear.

What Eloxx Pharmaceuticals Inc hinges on

Over the next one to three years, the thesis hinges on clinical and business progress, control of operating expenses, and access to financing. A weakening jobs trend could add pressure, while continued strength in Healthcare bellwethers could support the sector backdrop; misses or lower guidance from those companies could weaken that tailwind.